Abstract
In humans, nicotine has been demonstrated to improve both normal and disordered attention, suggesting potential clinical utility for nicotinic ligands. However, attempts to replicate these findings in the rodent have met with some difficulty, thus hampering the search for specific receptor mechanisms underlying these effects. In the present studies, we sought to characterize the effects of nicotine and subtype-selective ligands in a group of aged rats, which show consistent deficits in sustained attention over prolonged sessions of responding in the five-choice serial reaction time task (5-CSRTT). Following the establishment of a replicable performance improvement with nicotine (0.4 mg/kg), we assessed the effects of both SIB 1765F (1–5 mg/kg) and AR-R17779 (20 mg/kg), agonist ligands with selective affinities for the α4β2 and α7 receptor sites, respectively. We then attempted to block this effect of nicotine using the high affinity, competitive nicotinic antagonist DHβE (3 mg/kg). Finally, in an attempt to determine whether the psychostimulant profile of nicotinic agonists could be dissociated from their effects on attention, we compared the (R)- and (S)-enantiomers of SIB 1765F in the 5-CSRTT, and in their ability to increase locomotor activity. Reversal of a within-session decline in performance speed and accuracy by nicotine was mimicked by SIB 1765F, but not by AR-R17779, whereas DHβE antagonized all of the performance changes induced by nicotine. Finally, the (S)- but not the (R)-enantiomer increased locomotor activity and improved performance in the 5-CSRTT. These results support a critical involvement for the α4β2 nicotinic receptor in mediating the attention-enhancing properties of nicotine.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Benwell MEM, Balfour DJK (1992). The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 105: 849–856.
Blondel A, Sanger DJ, Moser PC (2000). Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology 149: 293–305.
Blondel A, Simon H, Sanger DJ, Moser PC (1999). Characterisation of the receptor subtypes mediating the effects of nicotine in the 5-choice reaction time task. J Psychopharmacol 13(Suppl.): P160, A50.
Carli M, Robbins TW, Evenden JL, Everitt BJ (1983). Effects of lesions to ascending noradrenergic neurons on performance of a 5-choice serial reaction time task in rats: implications for theories of dorsal bundle noradrenergic function based on selective attention and arousal. Behav Brain Res 9: 361–380.
Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC (1997). Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in xenopus oocytes. J Pharmacol Exp Ther 280: 346–356.
Clarke PBS, Kumar R (1983a). The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 78: 329–337.
Clarke PBS, Kumar R (1983b). Characterization of the locomotor stimulant action of nicotine in tolerant rats. Br J Pharmacol 80: 587–594.
Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH et al (1996). Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull 32: 67–73.
Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H et al (1996). (S)-(−)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 39: 3235–3237.
Gordon J, Gurley DA, Tran O, Machulskis A, Zongrone J, Luhowskylj S et al (1998). AR-R17779: the first high affinity, subtype-selective full agonist at the rodent α7 nicotinic acetylcholine receptor. Soc Neurosci Abstr 24: 331.9.
Grottick AJ, Higgins GA (2000). Effect of subtype selective nicotinic compounds on attention as assessed by the 5-choice serial reaction time task. Behav Brain Res 117: 197–208.
Grottick AJ, Higgins GA (2002). Assessing a vigilance decrement in aged rats: effects of pre-feeding, task manipulation, and psychostimulants. Psychopharmacology 164: 33–41.
Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R et al (2000a). Evidence that nicotinic α7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294: 1112–1119.
Grottick AJ, Wyler R, Higgins GA (2000b). The α4β2 agonist SIB 1765F, but not the α7 agonist AR-R17779 cross-sensitises to the psychostimulant effects of nicotine. Psychopharmacology 150: 233–236.
Grottick AJ, Wyler R, Higgins GA (2001). A study of the nicotinic agonist SIB-1553A on locomotion, and attention as measured by the 5-choice serial reaction time task. Pharmacol Biochem Behav 70: 505–513.
Gurley DA, Lanthorn T, Ryan T, Luhowskyj S, Gordon J (1998). Comparison of nicotine and the alpha 7-selective agonist AR-R17779 on nAchR α7 expressed in Xenopus oocytes. Soc Neurosci Abstr 24: 331.10.
Hahn B, Shoaib M, Stolerman IP (2001). Attentional effect of nicotinic agonists in rats. Soc Neurosci Abstr 31: 313.18.
Harvey SC, Luetje CW (1996). Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J Neurosci 16: 3798–3806.
Louis M, Clarke PBS (1998). Effect of ventral tegmental 6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats. Neuropharmacology 37: 1503–1513.
Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992). Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in disease. Psychopharmacology 108: 485–494.
Koelega HS (1993). Stimulant drugs and vigilance performance: a review. Psychopharmacology 111: 1–16.
Levin ED, Bettegowda C, Blosser J, Gordon J (1999). AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 10: 675–680.
Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D Meck WH et al (1996). Nicotine effects on adults with attention deficit hyperactivity disorder. Psychopharmacology 123: 55–63.
Luetje CW, Patrick J (1991). Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci 11: 837–845.
Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK (1997). Effects of a novel cholinergic ion channel agonist SIB1765F on locomotor activity in rats. J Pharmacol Exp Ther 280: 384–392.
Mirza NR, Stolerman IP (1998). Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology 138: 266–274.
Parasuraman R, Davies DR (1976). Decision theory analysis of response latencies in vigilance. J Exp Psychol Hum Percept Perform 2: 569–583.
Reavill C, Stolerman IP (1990). Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br J Pharmacol 99: 273–278.
Reid RT, Saccan AI, Adams PB, Correa LD, Santori EM, McDonald IA et al (1997). Pharmacological characterisation of SIB-1553A, a novel, subtype-selective neuronal nicotinic acetyl choline receptor (nAChR) agonist. Soc Neurosci Abstr 23: 477.17.
Sacaan I, Reid RT, Santori EM, Addmas P, Correa LD, Mahaffy LS et al (1997). Pharmacological characterisation of SIB-1765F: a novel cholinergic ion channel agonist. J Pharmacol Exp Ther 280: 373–383.
Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989). The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154: 797–800.
Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM et al (1997). Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther 74: 21–25.
Smith A, Nutt D (1996). Noradrenaline and attention lapses. Nature 380: 291.
Stolerman IP, Chandler CJ, Garcha HS, Newton JM (1997). Selective antagonism of behavioural effects of nicotine by dihydro-beta-erythroidine in rats. Psychopharmacology 129: 390–397.
Vernier JM, El-Abdellaoui H, Holsenback H, Cosford ND, Bleicher L, Barker G et al (1999). 4-[[2-(1-Methyl-2-pyrrol-idinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 42: 1684–1686.
Wesnes K, Warburton DM (1984). Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82: 147–150.
White HK, Levin ED (1999). Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 143: 158–165.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grottick, A., Haman, M., Wyler, R. et al. Reversal of a Vigilance Decrement in the Aged Rat by Subtype-Selective Nicotinic Ligands. Neuropsychopharmacol 28, 880–887 (2003). https://doi.org/10.1038/sj.npp.1300102
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300102
Keywords
This article is cited by
-
Convergent observations of MK-801-induced impairment in rat 5C-CPT performance across laboratories: reversal with a D1 but not nicotinic agonist
Psychopharmacology (2021)
-
Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects
Psychopharmacology (2020)
-
MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs
Psychopharmacology (2017)
-
Premature responses in the five-choice serial reaction time task reflect rodents’ temporal strategies: evidence from no-light and pharmacological challenges
Psychopharmacology (2016)
-
A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment
Psychopharmacology (2016)
